Determinants of medication use for the secondary prevention of cardiovascular disease מאת Thalmann, I

Symptomatic SARS-CoV-2 episodes and health-related quality of life מאת Alacevich, C, Thalmann, I, Nicodemo, C, de Lusignan, S, Petrou, S

Depression and anxiety during and after episodes of COVID-19 in the community מאת Alacevich, C, Thalmann, I, Nicodemo, C, de Lusignan, S, Petrou, S

Quality of care for secondary cardiovascular disease prevention in 2009–2017: population-wide cohort study of antiplatelet therapy use in Scotland מאת Thalmann, I, Preiss, D, Schlackow, I, Gray, A, Mihaylova, B

Antiplatelet therapy use for the secondary prevention of cardiovascular disease in 2009-2017: a population-wide retrospective cohort study of Scotland מאת Thalmann, I, Preiss, DJ, Schlackow, I, Gray, A, Mihaylova, B

Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009–2017 מאת Thalmann, I, Preiss, D, Schlackow, I, Gray, A, Mihaylova, B